Meeting
2023 ASCO Genitourinary Cancers Symposium
Association of liver metastases, tumor microenvironment, and treatment outcomes in patients with urothelial bladder cancer treated with tislelizumab.
Authors
Linlin Xu
Clinical biomarkers, BeiGene USA, Inc, San Mateo, CA
Linlin Xu , Mo Liu , Ruiqi Huang , Xiaopeng Ma , Xikun Wu , Vanitha Ramakrishnan , Lilin Zhang , Yun Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT04004221
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 537)
DOI
10.1200/JCO.2023.41.6_suppl.537
Abstract #
537
Poster Bd #
L20
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Pilot evaluation of PD-1 inhibition in metastatic cancer patients with liver transplantations (LT): The Mayo Clinic experience.
First Author: Thomas DeLeon
Poster
2016 ASCO Annual Meeting
Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).
First Author: Nicole Grace Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Peter Joel Hosein
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Galectin-9 as a regulator of immune interactions in the tumor microenvironment and novel therapeutic target in biliary tract cancer.
First Author: Emilie AK Warren